Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Humphrey, K A
1667  Ergebnisse:
Personensuche X
?
1

Glofitamab plus immunochemotherapy demonstrates durable eff..:

Townsend, W. ; Topp, M. S. ; Dickinson, M....
Hematological Oncology.  41 (2023)  S2 - p. 595-597 , 2023
Link: https://doi.org/10.1002/..
 
?
2

GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY..:

Dickinson, M. ; Carlo‐Stella, C. ; Morschhauser, F....
Hematological Oncology.  41 (2023)  S2 - p. 144-146 , 2023
Link: https://doi.org/10.1002/..
 
?
3

Analysis of immune and high‐risk biomarkers in patients wit..:

Pham*, T. H. ; Leung*, W. ; Hamidi, H....
Hematological Oncology.  41 (2023)  S2 - p. 486-488 , 2023
Link: https://doi.org/10.1002/..
 
?
4

P1210: IMMUNE CORRELATES OF RESPONSE TO GLOFITAMAB: BIOMARK..:

Piccione, E. C. ; Belousov, A. ; Hamidi, H....
HemaSphere.  6 (2022)  - p. 1096-1097 , 2022
Link: https://doi.org/10.1097/..
 
?
5

S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HA..:

Dickinson, M. ; Carlo-Stella, C. ; Morschhauser, F....
HemaSphere.  6 (2022)  - p. 121-122 , 2022
Link: https://doi.org/10.1097/..
 
?
6

Boosting the performance of Brillouin amplification at sub-..:

Trines, R M G M ; Alves, E P ; Humphrey, K A...
Plasma Physics and Controlled Fusion.  63 (2021)  12 - p. 124003 , 2021
Link: https://doi.org/10.1088/..
 
?
7

A robust plasma-based laser amplifier via stimulated Brillo..:

Alves, E P ; Trines, R M G M ; Humphrey, K A...
Plasma Physics and Controlled Fusion.  63 (2021)  11 - p. 114004 , 2021
Link: https://doi.org/10.1088/..
 
?
8

GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH ..:

Carlo‐Stella, C ; Hutchings, M ; Offner, F. C...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
9

IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFF..:

Morschhauser, F. ; Flinn, I.W. ; Gasiorowski, R....
Hematological Oncology.  37 (2019)  S2 - p. 135-137 , 2019
Link: https://doi.org/10.1002/..
 
?
10

GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLS..:

Tausch, E. ; Bahlo, J. ; Robrecht, S....
Hematological Oncology.  37 (2019)  S2 - p. 84-86 , 2019
Link: https://doi.org/10.1002/..
 
?
11

FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AN..:

Fischer, K. ; Porro Lurà, M. ; Al‐Sawaf, O....
Hematological Oncology.  37 (2019)  S2 - p. 82-84 , 2019
Link: https://doi.org/10.1002/..
 
?
12

HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS W..:

Al‐Sawaf, O. ; Lilienweiss, E. ; Bahlo, J....
Hematological Oncology.  37 (2019)  S2 - p. 104-106 , 2019
Link: https://doi.org/10.1002/..
 
?
13

IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/..:

Wu, J. ; Bolen, C. ; Seymour, J.F....
Hematological Oncology.  37 (2019)  S2 - p. 106-108 , 2019
Link: https://doi.org/10.1002/..
 
?
14

Role of CD20 expression and other pre-treatment risk factor..:

Freeman, C L ; Dixon, M ; Houghton, R...
Leukemia.  30 (2016)  8 - p. 1763-1766 , 2016
Link: https://doi.org/10.1038/..
 
?
15

Pricing American Put Options Using the Mean Value Theorem:

Tung, Humphrey K.K.
Journal of Futures Markets.  36 (2015)  8 - p. 793-815 , 2015
Link: https://doi.org/10.1002/..
 
1-15